Zacks Investment Research downgraded shares of Pharming Group (OTCMKTS:PHGUF) from a hold rating to a sell rating in a report published on Wednesday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

Several other research analysts have also recently commented on the stock. ValuEngine cut shares of Pharming Group from a hold rating to a sell rating in a report on Friday, December 1st. HC Wainwright reiterated a buy rating on shares of Pharming Group in a report on Thursday, October 26th.

Pharming Group (PHGUF) traded up $0.05 during midday trading on Wednesday, reaching $1.50. 325 shares of the company’s stock traded hands, compared to its average volume of 77,231. The company has a quick ratio of 1.27, a current ratio of 1.77 and a debt-to-equity ratio of 11.72. Pharming Group has a 12 month low of $0.30 and a 12 month high of $1.58.

COPYRIGHT VIOLATION WARNING: “Pharming Group (PHGUF) Rating Lowered to Sell at Zacks Investment Research” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/pharming-group-phguf-rating-lowered-to-sell-at-zacks-investment-research/1805797.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.